{"entity":{"id":"nct05077449","kind":"trial","name":"A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer","aka":[],"tldr":"A phase 3 trial testing XZP-3287 in HR-positive / HER2-negative breast cancer, active and no longer recruiting.","summary":"A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer is a phase 3 interventional study registered as NCT05077449, led by Xuanzhu Biopharmaceutical, and active but no longer recruiting on the registry. Official title: A Phase III Study to Evaluate the Efficacy and Safety of XZP-3287 in Combination With Fulvestrant Versus Placebo Combined With Fulvestrant in Patients With HR Positive and HER2 Negative Recurrent/Metastatic Breast Cancer. Planned enrolment is 300 participants (estimated). The study started in 2021-11-16 and primary completion is expected in 2024-02-22. No results have been posted on ClinicalTrials.gov.","status":"active","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT05077449","url":"https://clinicaltrials.gov/study/NCT05077449"}],"tags":["ctgov-ingest"],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["xzp-3287"],"companies":["xuanzhu-biopharmaceutical"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct05077449-nat-commun-2025"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05077449","phase":"3","setting":"A Phase III Study to Evaluate the Efficacy and Safety of XZP-3287 in Combination With Fulvestrant Versus Placebo Combined With Fulvestrant in Patients With HR Positive and HER2 Negative Recurrent/Metastatic Breast Cancer","sponsor":"Xuanzhu Biopharmaceutical","started":"2021-11-16","startedType":"actual","enrolled":300,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05077449/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"drug":[{"id":"xzp-3287","kind":"drug","name":"XZP-3287","route":"/drugs/xzp-3287/"}],"company":[{"id":"xuanzhu-biopharmaceutical","kind":"company","name":"Xuanzhu Biopharmaceutical","route":"/companies/xuanzhu-biopharmaceutical/"}],"paper":[{"id":"paper-nct05077449-nat-commun-2025","kind":"paper","name":"Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis","route":"/key-papers/paper-nct05077449-nat-commun-2025/"}]}}